Regeneron shares (NASDAQ:REGN) surged today after its Aflibercept met primary endpoints in two global trials for diabetic macular edema (DME) and wet age-related macular degeneration (wAMD).
Importantly, a major part of the patients in the trials was initiated and maintained at dosing intervals of 12 and 16 weeks.
Further, in the trials, the safety of aflibercept was consistent with that of EYELEA. The data are expected to be submitted to regulators globally.
The durability of the data and the safety profile of the drug could potentially make it a new standard of care for both diseases.
What Is the Target Price for Regeneron Stock?
The consensus rating for REGN is a Moderate Buy at present and an average price target of $660.92 implies the stock may correct by 6.54% after today’s rally.
Read full Disclosure
